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ABSTRACT
Dynamic protein–protein interactions between
proapoptotic and pro-survival Bcl-2 family members
regulate outer-mitochondrial membrane permeabi-
lization and cytochrome c release, key events in the
path to apoptosis. Their relative levels often dictate
the fate of a cell following an apoptotic stimulus. How-
ever, in cancer cells, the pro-survival Bcl-2 family
members are frequently upregulated, thereby creating
a constitutive block to apoptosis and resulting in con-
tinued cell survival under conditions that normally re-
sult in cell death. Because many chemotherapeutics
used to treat cancer also trigger apoptosis, this
upregulation of pro-survival members also contributes
to resistance to conventional cancer therapies. Strate-
gies that inactivate pro-survival Bcl-2 family mem-
bers therefore suggest a means by which this
downstream block in apoptosis can be alleviated, re-
sulting in the selective killing of malignant cells. Here,
we outline the progress of three small-molecule Bcl-2
antagonists that have advanced into clinical evaluation.
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1. INTRODUCTION
Apoptosis evolved in metazoans as a means to main-
tain tissue homeostasis by eliminating unwanted or
damaged cells. By removing cells that have accumu-
lated genetic mutations that subvert normal growth
control, apoptosis forms a protective barrier against
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oncogenic transformation. In fact, evasion of apoptosis
is considered to be a hallmark of all cancers, because
cancer cells manifest stress signals such as transform-
ing oncogenes that trigger apoptosis and should result
in their self-elimination and corresponding abrogation
in tumour formation 1. Thus, for a cell to become ma-
lignant, it must first bypass the apoptotic machinery.
This task can be accomplished through either inactiva-
tion of apoptosis-inducing genes or activation of inhibi-
tors of apoptosis. Because many chemotherapeutic
drugs used to treat cancer also trigger apoptosis, eva-
sion of apoptosis may also contribute to the resistance
encountered in conventional cancer therapies.
2. THE BCL-2 FAMILY
Many apoptotic signals, such as DNA damage and
oncogene activation, initiate signalling cascades that
converge on the permeabilization of the outer mito-
chondrial membrane (OMM). This membrane
permeabilization leads to the release of cytochrome c
from the inter-membrane space, resulting in the acti-
vation of a family of aspartate-specific cysteine
proteases, termed caspases. Activated caspases in turn
cleave numerous cellular proteins, resulting in the
morphology known as apoptosis and, ultimately, in cell
destruction 2–4. These pathways are both executed and
regulated by the Bcl-2 family of proteins, which com-
prise three groups, defined according to function and
to Bcl-2 homology (BH) domain content 5–8:
￿ The proapoptotic effectors, including Bax and Bak,
contain BH1, BH2, and BH3, and a C-terminal trans-
membrane segment that selectively targets these
proteins to the membranes of mitochondria and en-
doplasmic reticulum. Bax and Bak are present as
inactive monomers under normal conditions; how-
ever, following a death signal, they can undergo
homo- and hetero-oligomerization within the OMM,
causing OMM permeabilization and the egress of
cytochrome c from the inter-membrane space.
They form an essential gateway for the mitochon-
drial apoptotic pathway: mice deficient in both Bax
and Bak are resistant to all tested intrinsic apoptotic
signals 9,10.
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￿ The pro-survival members Bcl-2, Mcl-1, Bcl-xl,
Bcl-w, and A1 have the same overall architecture
as Bax and Bak, but with the exception of Mcl-1,
they also contain a BH4 domain located toward their
N-terminus.
￿ The last group, a large and diverse proapoptotic
group within this family, contains only a single BH3
domain and includes Bim, Puma, Bid, Bad, Bik,
Noxa, and others. They respond to death signals
upstream of Bax and Bak, resulting in their activa-
tion or upregulation (or both). The active BH3-only
members then facilitate transition of these signals
to the downstream multi-domain members 7,11.
The outcome of cell death signalling pathways
depends on a complex interplay involving physical in-
teractions between the pro-survival and pro-death mem-
bers. Structural studies have revealed that the BH3
domain adopts an alpha-helical conformation and that
the BH3 domain of a proapoptotic member is able to
bind to pro-survival members by occupying a hydro-
phobic pocket formed by the close proximity of their
BH1–3 domains 12,13.
The BH3-only proteins have been proposed to form
two distinct groups: those that sensitize cells to
apoptosis by binding to anti-apoptotic Bcl-2 proteins
(Puma, Bad, Noxa, and Bik), and those that in addition
directly activate proapoptotic Bax or Bak (Bim and
Bid) 14,15. In this model, apoptosis will not proceed
unless sufficient activator BH3-only proteins are
present, because sensitizer BH3-only proteins cannot
independently activate Bax and Bak. However, whether
BH3-only proteins can directly activate Bax and Bak,
or whether an additional activation event is even needed
for Bax and Bak oligomerization and cytochrome c
release is currently under debate 14,16–18. Similar con-
troversy exists concerning how the pro-survival mem-
bers inhibit Bax and Bak oligomerization; however, they
likely both function to sequester BH3-only proteins and
to antagonize Bak and Bax directly at the mitochon-
dria (Figure 1) 14,16,19.
Because many apoptotic pathways are regulated
and executed by the Bcl-2 family, the ratio between
pro-survival Bcl-2 family members and proapoptotic
members often dictates the fate of a cell following an
apoptotic stimulus. In cancer cells, this balance is of-
ten altered and thus provides a means for cancer cells
to evade apoptosis. The founding Bcl-2 family mem-
ber, Bcl-2, was identified at the chromosomal break-
point t14:18 in human follicular B-cell lymphoma,
resulting in its upregulation. Since this discovery, many
malignancies have been shown to overexpress Bcl-2
and other pro-survival family members 20,21. This
overexpression results in a constitutive block to Bax
and Bak oligomerization, thereby preventing transla-
tion of the upstream death signals to OMM permeabi-
lization (Figure 1). Strategies that target the functional
BH3-binding groove of these pro-survival Bcl-2 family
members in an attempt to reinstate an effective
apoptosis pathway therefore hold significant therapeu-
tic promise in oncology 22,23.
3. THE SMALL-MOLECULE BCL-2
ANTAGONISTS
Several small-molecule Bcl-2 antagonists have been
developed and are under preclinical evaluation. Here,
however, we focus on compounds that have advanced
into clinical trials.
3.1 Obatoclax
A high throughput screen used to identify molecules
that interrupt Bcl protein–protein interactions identi-
fied GX15-070 (obatoclax) 23,24. By fluorescence po-
larization assay, obatoclax has been reported to bind
the BH3 groove of all pro-survival members with low
micromolar affinity 25. However, obatoclax is particu-
larly hydrophobic and therefore insoluble in strictly
aqueous assays. The use of fluorescence polarization
assays or similar binding approaches to determine the
exact affinity of this compound for Bcl-2 family mem-
bers may therefore not be possible 24.
Notably, obatoclax disrupted the protection afforded
by Bcl-2, Mcl-1, Bcl-xl, and Bcl-w in a Bax and Bak
reconstituted yeast system, and inhibited colony for-
mation of Eμ–myc lymphoma cell lines overexpressing
Bcl-2, Mcl-1, and A1, suggesting that it can target
multiple pro-survival Bcl-2 family members 24.
Obatoclax displayed single-agent activity against mul-
tiple cancer cell lines, including non-small-cell lung
cancer (NSCLC), multiple myeloma (MM), and patient-
derived mantle-cell lymphoma, acute myelogenous
leukemia (AML), and chronic lymphocytic leukemia
(CLL) cells 26–31. In vivo tumour regression was seen
in xenograft models derived from prostate, cervical,
colon, and mammary carcinoma cell lines 24. Further-
more, obatoclax displayed synergy with bortezomib in
mantle-cell lymphoma and MM, with cisplatin in
NSCLC, with cytarabine in AML, and with fludarabine
in CLL 27–29,31.
Obatoclax-mediated apoptosis depends on Bax and
Bak, as evidenced by loss of caspase 3 activation and
DNA fragmentation in mouse kidney epithelial cells
doubly deficient in Bax and Bak 24. A number of groups
have reported that obatoclax cytotoxicity correlates with
the disruption of Mcl–Bak complexes as measured by
chemical crosslinking in isolated mitochondria and
immunoprecipitation 24,27,29–31, but disruption of Bcl-
xl–Bak, Mcl-1–Bim, and Bcl-2–Bim complexes have
also been noted 26,29,31. A substantial reduction in
apoptotic cells was observed in mouse embryonic
fibroblasts deficient in Bak and Bim, further suggest-
ing a central role for Bak and Bim in obatoclax-medi-
ated cytotoxicity 31. Obatoclax is currently being
investigated in phase I and II clinical trials as both a
single agent in CLL, AML, CLL, and Hodgkin lymphoma,
and in combination with other antitumor agents inSMALL-MOLECULE BCL-2 ANTAGONISTS
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hematologic, lymphoid, and solid-tumour malignancies.
(Details can be found at www.clinicaltrials.gov/ct2/
results?term=obatoclax.)
3.2 ABT-263
Nuclear magnetic resonance screening was used to de-
velop a small-molecule inhibitor of Bcl-xl. The result-
ing compound, ABT-737, binds with high affinity to
Bcl-2, Bcl-xl, and Bcl-w (Ki ≤ 1 nmol/L), but exhibits
minimal binding to Mcl-1 and A1 (Ki > 1 μmol/L) 32.
This behaviour is consistent with the agent’s ability to
inhibit colony formation of Eμ–myc lymphoma cell lines
overexpressing Bcl-2, but not Mcl-1 or A1 24. ABT-
737 showed single-agent activity against a variety of
established solid tumour, hematopoietic, and lymphoid
cancer cell lines, and against primary patient-derived
follicular lymphoma, acute lymphoblastic leukemia
(ALL), and MM cells 32–36. Furthermore, tumour
regression with limited toxicity was seen in small-cell
lung cancer, MM, and AML tumour xenografts 32,35,37.
In addition, ABT-737 exhibited synergistic cytotoxic-
ity with paclitaxel in NSCLC cells, with etoposide in
NSCLC xenografts, and with bortezomib, melphalan,
and dexamethasone in MM cells 32,33,35,37.
Mechanistically, ABT-737 has been shown to dis-
rupt Bcl-2–Bim and Bcl-2–Bax complexes as demon-
strated by immunoprecipitation 35,38. Furthermore,
apoptosis induction was greatly diminished in Bak-,
Bax-, and doubly-deficient mouse embryonic
fibroblasts, suggesting that ABT-737–mediated cyto-
toxicity requires both Bak and Bax 35. More recently,
an orally available analog of ABT-737, ABT-263, which
has a similar binding profile, has been created 39 and
is currently in early phase I and II clinical trials as a
single agent for a variety of hematologic, lymphoid,
and solid-tumour malignancies. (Details can be found
at www.clinicaltrials.gov/ct2/results?term=abt263.)
FIGURE 1   Regulation of mitochondrial apoptotic pathway by the Bcl-2 protein family. The schematic details how the Bcl-2 family integrates
upstream death signals to Bax and Bak oligomerization, permeabilization of the outer mitochondrial membrane (OMM), and release of
cytochrome c. Overexpression of pro-survival Bcl-2 family members block Bax and Bak oligomerization, resulting in cell survival.WARR and SHORE
259 259 259 259 259
CURRENT ONCOLOGY—VOLUME 15, NUMBER 6
3.3 (–)-Gossypol
Gossypol is a natural product isolated from cottonseeds
that has been studied previously for a variety of thera-
peutic uses. More recently, it was found that the (–)
enantiomer of gossypol (AT-101) binds with nanomolar
affinity to Bcl-2 (320 nmol/L), Bcl-xl (480 nmol/L),
and Mcl-1 (180 nmol/L) 40. Single-agent activity of (–)-
gossypol has been shown in a variety of cancer cell
lines, including CLL, prostate and colon carcinoma, and
patient-derived MM and diffuse large-cell lymphoma
cells 41–46. Furthermore, synergy was seen with dex-
amethasone in MM and with docetaxel in prostate can-
cer cell lines 42,43. In addition, (–)-gossypol was shown
to be effective with cyclophosphamide and rituximab
in a B-cell lymphoma xenograft model 47.
Mechanistically, gossypol has been shown to dis-
rupt Bcl-xl–Bim and Bcl-xl–Bax complexes 44. How-
ever, gossypol has recently been shown to induce
apoptosis in a Bax- and Bak-independent manner by
converting Bcl-2 into a proapoptotic molecule 48. No-
tably, the conversion was accomplished using a mix-
ture of gossypol enantiomers, suggesting that tests
should be repeated with (–)-gossypol alone. Further work
needs to be done to ascertain gossypol’s primary mecha-
nism of action. Currently, (–)-gossypol is being evalu-
ated in phase I and II clinical trials as a single agent in
B-cell malignancies and prostate cancer, and in com-
bination with other antitumor agents in a variety of
hematologic, lymphoid, and solid-tumour malignancies.
(Details can be found at clinicaltrials.gov/ct2/
results?term=gossypol.)
4. MCL-1: A CRITICAL TARGET IN CERTAIN
MALIGNANCIES
Genetic mouse models have demonstrated that pro-
survival Bcl-2 family members play critical, non-re-
dundant roles in the development and maintenance of
normal tissues 49. In addition to varied expression, this
property of Bcl-2 proteins may be at least partly ex-
plained by the existence of considerable BH3-depend-
ent binding preferences between pro-survival Bcl-2
family members and their proapoptotic partners 14,19,50.
For example, Bim and Puma have been shown to in-
teract with high affinity with all pro-survival mem-
bers, but Noxa and Bad interact selectively only with
Mcl-1 and A1, and with Bcl-2, Bcl-xl, and Bcl-w re-
spectively 14,50.
The ABT-737 molecule, which does not bind Mcl-
1 and A1, and which therefore has a binding profile
similar to that of Bad, exhibits single-agent cytotoxic-
ity in select tumour models as described. However,
ABT-737 encounters marked resistance under condi-
tions in which Mcl-1 is elevated 24,38,51,52. Correspond-
ingly, targeted downregulation of Mcl-1 by short
interfering RNA sensitizes cells resistant to ABT-737
in a number of malignancies 24,35,52–55. This interfer-
ence correlates with the inability of ABT-737 to
effectively bind and neutralize Mcl-1 32. Therefore, to
bypass cancer cell survival with a Bcl-2 antagonist,
neutralizing Mcl-1 appears to be critical in certain tu-
mour environments.
A variety of means could be employed to combat
resistance encountered by Mcl-1. These include the
use of a high-affinity pan–Bcl-2 inhibitor (although this
approach may increase toxicity), combinational use of
multiple Bcl-2 antagonists, or subsequent treatment
with agents that diminish Mcl-1 levels. In fact,
obatoclax (which has been shown to displace
proapoptotic members from Mcl-1) and etoposide,
carboplatin, sorafenib, and seliciclib (all of which have
been shown to reduce Mcl-1 levels) can synergize
with ABT-737 to overcome Mcl-1–mediated resist-
ance 24,52–55. Of course, use of a selective small-mol-
ecule inhibitor to inactivate Mcl-1 protein levels
represents a considerably more direct way of targeting
Mcl-1–mediated resistance, and therefore may allow
for greater functional utility.
Resistance to ABT-737 mediated by Mcl-1 pro-
vides an example of the complexity involved in target-
ing pro-survival Bcl-2 family members in cancer.
Furthermore, it ultimately suggests that the efficacy of
small-molecule Bcl-2 antagonists in the clinic will
depend on neutralizing the pertinent pro-survival mem-
ber or members that are selectively sequestering
proapoptotics needed to link an upstream death signal
to downstream caspase activation.
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